Wells Fargo analyst Larry Biegelsen downgraded RxSight to Equal Weight from Overweight with a price target of $14, down from $20.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on RXST:
Wells Fargo analyst Larry Biegelsen downgraded RxSight to Equal Weight from Overweight with a price target of $14, down from $20.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on RXST: